Hoth Therapeutics' HT-KIT Receives FDA Orphan Drug Status with Strong Preclinical Results

Hoth Therapeutics announces FDA Orphan Drug Designation for HT-KIT, showing >80% tumor suppression in preclinical trials for systemic mastocytosis and GIST.